Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis [PDF]
The Journal of Headache and PainBackground Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data.
Wattakorn Laohapiboolrattana +7 more
doaj +3 more sources
Preventive and abortive treatment of migraine with traditional drugs - the state of the art
Headache Medicine, 2023 Introduction Migraine is a chronic neurological disease, with a prevalence of 15.2% in Brazil. It is 2.2 times more prevalent in women, predominantly in the 18-50 age group. Its pathophysiological mechanism is still not completely understood.
Raimundo Pereira Silva-Néto +2 more
doaj +2 more sources
The Journal of Headache and Pain, 2022 Background 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migraine attacks and inhibit the in vivo ...
Jacob C. A. Edvinsson +7 more
doaj +2 more sources
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
Pharmaceuticals, 2021 Migraine is the second cause of disability and of lost years of healthy life worldwide. Migraine is characterized by recurrent headache attacks and accompanying disabling symptoms lasting 4–48 h.
Damiana Scuteri, Giacinto Bagetta
doaj +2 more sources
New therapeutic options in migraine treatment [PDF]
Journal of Education, Health and SportIntroduction and purpose Migraine is a common disease mostly affecting women. It has a huge influence on patients’ life strongly decreasing its quality by cause of repetitive headache episodes and often comes with unpleasant and burdensome symptoms ...
Aleksandra Kłos +9 more
doaj +4 more sources
Emerging Pharmacological Treatments for Migraine in the Pediatric Population [PDF]
Life, 2022 Headaches in children and adolescents have high incidence and prevalence rates, with consequent elevated disability costs to individuals and the community. Pediatric migraine is a disorder with substantial clinical differences compared to the adult form.
Luigi Francesco Iannone +2 more
doaj +2 more sources
Therapeutic novelties in migraine: new drugs, new hope? [PDF]
The Journal of Headache and Pain, 2019 Background In the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.
Thien Phu Do, Song Guo, Messoud Ashina
doaj +2 more sources
Pharmacogenetics in Primary Headache Disorders
Frontiers in Pharmacology, 2022 Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals
Irina I. Belyaeva +11 more
doaj +2 more sources
Prevalence, Treatment, and Unmet Needs of Migraine in the Middle East: A Systematic Review [PDF]
Pain and TherapyIntroduction Migraine is a debilitating neurological disorder characterized by recurrent throbbing, moderate-to-severe headaches that disrupt daily chores, leisure, and social activities of patients, impacting their overall quality of life (QoL). Despite
Taoufik Alsaadi +10 more
doaj +2 more sources
The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review [PDF]
Pain and TherapyIntroduction Thirty years ago, the first migraine-specific drugs (triptans) appeared. Today two new categories (gepants and ditans) are marketed for acute migraine treatment. That said, is there still a role for conventional therapy?
Piero Barbanti +5 more
doaj +2 more sources